Programmable Large-DNA Integration
RNA-guided transposases and bridge-RNA recombinases insert whole genes or multi-kilobase cargo at chosen sites without relying on double-strand-break repair.
Developed mainly in: United StatesImpacting: North America and Europe
Cornell researchers engineered a hybrid gene editing system in bacteria by joining protein components that never pair in nature, including RNA-guided enzymes thought to be evolutionary precursors of CRISPR-Cas. Separate experiments re-engineered an existing CRISPR-Cas system to place genetic payloads more accurately and reduce off-target insertions. Work so far is bacterial, with plant, animal and…
This is one of 24 signals scored in our latest scan.
Track Them Free For 14 Days →Since we flagged this
First flagged
25 March 2026 · score 9.0/10
Corroborating sources since flagging
10
Latest signals
Tracked from 3 signals, each traced to its source.
- Cornell team fuses ancestral RNA-guided enzymes with transposases for precise DNA insertion
News · 8 Oct 2026
- Optimization of IS621 recombinase/bridge RNA-directed recombination for precise insertion of large DNA fragments in human cells
Nature · 20 Jun 2026
- Programmable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase
Science · 25 Mar 2026
In the full record
Evolution
Score over time, Score Jumps and how the evidence built up since the first signal.
Thesis
Paradigm Shift, Commercial Viability, signal strength and the driver of the change.
Why this innovation matters
The full analysis: what is shifting, who is affected and the second-order effects.
Forecasted Hypothesis
What would strengthen this innovation, and what would weaken it.
Exposure
Companies and publicly listed stock symbols linked to this innovation.
Every signal
Each signal with its date, score, flags and original source.
Open the full record free for 14 days → No card needed.
More in Biotech
Other innovations the engine is currently tracking in this industry.
- Virtual Trial Outcome Prediction7.0/ 10 · 2 signals
- Multi-Receptor Incretin Co-Agonists6.8/ 10 · 5 signals
- Programmable RNA And Expression Control7.7/ 10 · 3 signals
- Multivalent Seasonal Respiratory mRNA Vaccines6.5/ 10 · 2 signals
- Novel Food Approval Pathways For Cultivated Meat6.9/ 10 · 7 signals
- Clinical Genome-Editing Therapeutics7.8/ 10 · 6 signals
Track every innovation, free for 14 days
Full Analyst access from the first day. No card. Then subscribe to keep it.
- The radar: every innovation, ranked by Disruption Score
- Tracked evolution: score over time, Score Jumps and how the evidence built up
- Thesis and analysis: Commercial Viability, Paradigm Shift, why it matters, what would change it
- Geography: where each innovation is developed and where it has impact
- Exposure: the companies and public stock symbols behind each innovation
- Every signal with its source, and what moved since your last visit
- Email alerts when an innovation moves: First Signal, Score Jump and briefings
Disclaimer: The information provided on this page is for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Stock data shown is illustrative and may not reflect real-time prices. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.